Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
03/20/2017 03/21/2017 03/22/2017 03/23/2017 03/24/2017 Date
56.41(c) 55.71(c) 56.36(c) 55.77(c) 55.89(c) Last
8 481 366 9 394 520 9 808 349 7 624 712 6 121 960 Volume
+0.21% -1.24% +1.17% -1.05% +0.22% Change
More quotes
Financials ($)
Sales 2017 19 706 M
EBIT 2017 5 203 M
Net income 2017 4 660 M
Finance 2017 232 M
Yield 2017 2,91%
Sales 2018 20 362 M
EBIT 2018 5 559 M
Net income 2018 5 180 M
Finance 2018 1 426 M
Yield 2018 2,95%
P/E ratio 2017 20,19
P/E ratio 2018 18,51
EV / Sales2017 4,66x
EV / Sales2018 4,45x
Capitalization 92 079 M
More Financials
Company
Bristol-Myers Squibb Co. operates as a biopharmaceutical company, which engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products.Its pharmaceutical products include chemically-synthesized drugs or small molecules and products... 
Sector
Pharmaceuticals
Calendar
04/05Ex-dividend day
More about the company
Surperformance© ratings of Bristol-Myers Squibb Co
Trading Rating : Investor Rating :
More Ratings
Latest news on BRISTOL-MYERS SQUIBB CO
03/24 BRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion Recommending Opdivo (nivol..
03/23 BRISTOL-MYERS SQUIBB COMPANY (OTCMKT : BMYMP) Files An 8-K Departure of Director..
03/23 BRISTOL MYERS SQUIBB CO : Change in Directors or Principal Officers (form 8-K)
03/23 FINDINGS FROM BRISTOL-MYERS SQUIBB C : An HCV Protease Inhibitor With Preferenti..
03/23 BRISTOL MYERS SQUIBB : Patent Issued for Crystalline Forms of N,N-Dicyclopropyl-..
03/23 BRISTOL MYERS SQUIBB : Patent Issued for Crystalline Form of N,N-Dicyclopropyl-4..
03/23 BRISTOL MYERS SQUIBB : Patent Issued for Sensitive Method to Analyse Free PEG-Ma..
03/23 BRISTOL MYERS SQUIBB : to Announce Results for First Quarter 2017 on April 27
03/22 BRISTOL MYERS SQUIBB : CytomX pen expanded $3.6B biobucks research deal
03/20 BRISTOL MYERS SQUIBB : and CytomX Therapeutics Extend Worldwide Collaboration to..
More news
Sector news : Pharmaceuticals - NEC
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on BRISTOL-MYERS SQUIBB CO 
2016Attractive price levels
More Strategies
Latest Tweets
03/24Want the latest upgrades & downgrades for $BMY $EMR $DHI $CSX $BNED? Chec.. 
03/24Trump Effect: Week In Review $BWXT $MYL $CELG $BMY $LLY $PFE $ABBV $AMGN $VRX..
1
03/24$BMY: Bristol-Myers confirms the CHMP has recommended the approval of Opdivo .. 
03/24BRIEF-Bristol-Myers Squibb receives positive CHMP opinion recommending opdivo.. 
03/24European advisory committee backs Bristol-Myers' Opdivo for head and neck can.. 
More tweets
Qtime:96
News from SeekingAlpha
03/24 European advisory committee backs Bristol-Myers' Opdivo for head and neck can..
03/23 Bristol Failure Makes Small Dent In CXCR4-Blocking Approach
03/23 Pharma Development Budgets Grow As Roche Remains A Believer
03/21 Biotechs under pressure after Trump (again) decries high drug prices
03/21 Selling Or Trimming Reasons Within My 86 Stock Portfolio
Advertisement
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 55,3 $
Spread / Average Target -1,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-4.36%92 079
JOHNSON & JOHNSON8.91%340 163
ROCHE HOLDING LTD.8.60%219 545
PFIZER INC.4.68%202 474
NOVARTIS AG-0.94%195 096
MERCK & CO., INC.7.32%173 465
More Results